Literature DB >> 35355203

Management of Atrial Tachyarrhythmias in Heart Failure-an Interventionalist's Point of View.

Jason A Gencher1, Nathaniel M Hawkins1,2, Marc W Deyell1,2, Jason G Andrade3,4,5.   

Abstract

PURPOSE OF REVIEW: Atrial fibrillation (AF) and heart failure (HF) are commonly encountered clinical disorders that often co-exist, accelerating disease progression and adverse outcomes. It is known that restoration of sinus rhythm positively impacts this population; however, the complex comorbidity profile associated with HF introduces intricacies not encountered in other patient populations. The current review focuses on the safety and efficacy of an interventional-based management for atrial tachyarrhythmias in HF. RECENT
FINDINGS: While pharmacotherapy has been the standard treatment of cardiac dysrhythmias in the HF population, recent evidence suggests catheter ablation is more effective and causes less harm than antiarrhythmic drugs (AADs) in the HF population. For the maintenance of sinus rhythm, catheter ablation results in improved freedom from recurrent arrhythmia, with secondary benefit on mortality and hospitalization in those with HF and reduced ejection fraction. For those with permanent AF, cardiac resynchronization therapy and atrioventricular junction ablation result in improved quality of life, physical functioning, and cardiac function.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Ablation; Antiarrhythmic drugs; Atrial fibrillation; Cardiomyopathy; Catheter ablation; Heart failure

Mesh:

Substances:

Year:  2022        PMID: 35355203     DOI: 10.1007/s11897-022-00543-4

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  48 in total

1.  Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial.

Authors:  Michael R MacDonald; Derek T Connelly; Nathaniel M Hawkins; Tracey Steedman; John Payne; Morag Shaw; Martin Denvir; Sai Bhagra; Sandy Small; William Martin; John J V McMurray; Mark C Petrie
Journal:  Heart       Date:  2010-11-04       Impact factor: 5.994

2.  Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.

Authors:  Ulrik M Mogensen; Pardeep S Jhund; William T Abraham; Akshay S Desai; Kenneth Dickstein; Milton Packer; Jean L Rouleau; Scott D Solomon; Karl Swedberg; Michael R Zile; Lars Køber; John J V McMurray
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

3.  A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial).

Authors:  Ross J Hunter; Thomas J Berriman; Ihab Diab; Ravindu Kamdar; Laura Richmond; Victoria Baker; Farai Goromonzi; Vinit Sawhney; Edward Duncan; Stephen P Page; Waqas Ullah; Beth Unsworth; Jamil Mayet; Mehul Dhinoja; Mark J Earley; Simon Sporton; Richard J Schilling
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-01-01

Review 4.  Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.

Authors:  Ayodele Odutayo; Christopher X Wong; Allan J Hsiao; Sally Hopewell; Douglas G Altman; Connor A Emdin
Journal:  BMJ       Date:  2016-09-06

5.  Meta-Analysis Comparing Catheter-Guided Ablation Versus Conventional Medical Therapy for Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction.

Authors:  Akram Y Elgendy; Ahmed N Mahmoud; Muhammad S Khan; Maryam R Sheikh; Mohammad K Mojadidi; Mohamed Omer; Islam Y Elgendy; Anthony A Bavry; Kenneth A Ellenbogen; William M Miles; Matthew McKillop
Journal:  Am J Cardiol       Date:  2018-06-05       Impact factor: 2.778

Review 6.  Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment.

Authors:  E Kevin Heist; Jeremy N Ruskin
Journal:  Prog Cardiovasc Dis       Date:  2006 Jan-Feb       Impact factor: 8.194

7.  Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.

Authors:  Luigi Di Biase; Prasant Mohanty; Sanghamitra Mohanty; Pasquale Santangeli; Chintan Trivedi; Dhanunjaya Lakkireddy; Madhu Reddy; Pierre Jais; Sakis Themistoclakis; Antonio Dello Russo; Michela Casella; Gemma Pelargonio; Maria Lucia Narducci; Robert Schweikert; Petr Neuzil; Javier Sanchez; Rodney Horton; Salwa Beheiry; Richard Hongo; Steven Hao; Antonio Rossillo; Giovanni Forleo; Claudio Tondo; J David Burkhardt; Michel Haissaguerre; Andrea Natale
Journal:  Circulation       Date:  2016-03-30       Impact factor: 29.690

8.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure.

Authors:  Mohammed N Khan; Pierre Jaïs; Jennifer Cummings; Luigi Di Biase; Prashanthan Sanders; David O Martin; Josef Kautzner; Steven Hao; Sakis Themistoclakis; Raffaele Fanelli; Domenico Potenza; Raimondo Massaro; Oussama Wazni; Robert Schweikert; Walid Saliba; Paul Wang; Amin Al-Ahmad; Salwa Beheiry; Pietro Santarelli; Randall C Starling; Antonio Dello Russo; Gemma Pelargonio; Johannes Brachmann; Volker Schibgilla; Aldo Bonso; Michela Casella; Antonio Raviele; Michel Haïssaguerre; Andrea Natale
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

9.  Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.

Authors:  D L Dries; D V Exner; B J Gersh; M J Domanski; M A Waclawiw; L W Stevenson
Journal:  J Am Coll Cardiol       Date:  1998-09       Impact factor: 24.094

10.  Meta-analysis of the Usefulness of Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Omar M Aldaas; Florentino Lupercio; Douglas Darden; Praneet S Mylavarapu; Chaitanya L Malladi; Frederick T Han; Kurt S Hoffmayer; David Krummen; Gordon Ho; Farshad Raissi; Ulrika Birgersdotter-Green; Gregory K Feld; Jonathan C Hsu
Journal:  Am J Cardiol       Date:  2020-12-05       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.